Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company, announced significant insider share purchases by its co-founders. CEO Michael Myers acquired 37,894 American Depositary Shares (ADSs) at prices ranging from $0.619 to $0.7974 per ADS on September 3-4, 2024. Similarly, COO Denise Carter purchased 37,735 ADSs between $0.6253 and $0.7965 per ADS during the same period.
These insider purchases are viewed as a strong signal of leadership confidence in Quoin's growth trajectory and commitment to delivering long-term shareholder value. The company focuses on developing and commercializing novel treatments for rare and orphan diseases, aiming to address unmet needs in underserved patient populations globally.
Quoin Pharmaceuticals (NASDAQ: QNRX), un'azienda farmaceutica specializzata in fase clinica, ha annunciato significativi acquisti di azioni da parte dei suoi cofondatori. Il CEO Michael Myers ha acquisito 37.894 American Depositary Shares (ADS) a prezzi compresi tra $0,619 e $0,7974 per ADS nei giorni 3 e 4 settembre 2024. Allo stesso modo, Il COO Denise Carter ha acquistato 37.735 ADS a prezzi tra $0,6253 e $0,7965 per ADS durante lo stesso periodo.
Questi acquisti da parte dei dirigenti sono visti come un forte segnale di fiducia della leadership nella traiettoria di crescita di Quoin e del suo impegno a fornire valore agli azionisti a lungo termine. L'azienda si concentra sullo sviluppo e sulla commercializzazione di trattamenti innovativi per malattie rare e orfane, con l'obiettivo di rispondere a bisogni non soddisfatti in popolazioni di pazienti svantaggiate a livello globale.
Quoin Pharmaceuticals (NASDAQ: QNRX), una empresa farmacéutica especializada en etapa clínica, anunció importantes compras de acciones por parte de sus cofundadores. El CEO Michael Myers adquirió 37,894 American Depositary Shares (ADS) a precios que oscilan entre $0.619 y $0.7974 por ADS el 3 y 4 de septiembre de 2024. De manera similar, la COO Denise Carter compró 37,735 ADS entre $0.6253 y $0.7965 por ADS durante el mismo período.
Estas compras por parte de los ejecutivos se consideran una señal clara de confianza en la trayectoria de crecimiento de Quoin y de su compromiso con proporcionar valor a largo plazo a los accionistas. La empresa se centra en desarrollar y comercializar tratamientos innovadores para enfermedades raras y huérfanas, con el objetivo de abordar necesidades no satisfechas en poblaciones de pacientes desatendidas en todo el mundo.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 임상 단계의 전문 제약회사로서 공동 창립자들의 중요한 내부 주식 구매를 발표했습니다. CEO 마이클 마이어스는 2024년 9월 3일부터 4일 사이에 ADS당 $0.619에서 $0.7974 사이의 가격으로 37,894개의 미국 예탁 주식(ADS)을 인수했습니다. 유사하게, COO 데니스 카터는 같은 기간 동안 ADS당 $0.6253에서 $0.7965 사이의 가격으로 37,735개의 ADS를 구매했습니다.
이러한 내부 구매는 Quoin의 성장 경로에 대한 리더십의 강한 확신과 장기 주주 가치를 제공하겠다는 약속의 신호로 여겨집니다. 이 회사는 희귀 및 고아 질병에 대한 새로운 치료제를 개발하고 상용화하는 데 중점을 두며, 전 세계적으로 서비스를 받지 못하는 환자군의 unmet needs를 해결하는 것을 목표로 하고 있습니다.
Quoin Pharmaceuticals (NASDAQ: QNRX), une société pharmaceutique spécialisée en phase clinique, a annoncé des achats d'actions significatifs de la part de ses cofondateurs. Le PDG Michael Myers a acquis 37 894 American Depositary Shares (ADS) à des prix variant entre 0,619 et 0,7974 USD par ADS les 3 et 4 septembre 2024. De même, Le COO Denise Carter a acheté 37 735 ADS entre 0,6253 et 0,7965 USD par ADS pendant cette même période.
Ces achats internes sont perçus comme un fort signe de confiance de la direction dans la trajectoire de croissance de Quoin et de son engagement à offrir de la valeur aux actionnaires à long terme. L'entreprise se concentre sur le développement et la commercialisation de traitements novateurs pour les maladies rares et orphelines, visant à répondre aux besoins non satisfaits de populations de patients mal desservies à travers le monde.
Quoin Pharmaceuticals (NASDAQ: QNRX), ein forschungsintensives Pharmaunternehmen in der klinischen Phase, hat bedeutende Insideraktienkäufe durch seine Mitgründer bekannt gegeben. CEO Michael Myers erwarb am 3. und 4. September 2024 insgesamt 37.894 American Depositary Shares (ADS) zu Preisen zwischen 0,619 und 0,7974 USD pro ADS. Ebenso kaufte COO Denise Carter im gleichen Zeitraum 37.735 ADS zu Preisen zwischen 0,6253 und 0,7965 USD pro ADS.
Diese Insiderkäufe werden als starkes Signal für das Vertrauen der Führung in die Wachstumsperspektiven von Quoin und das Engagement zur Schaffung von langfristigem Wert für die Aktionäre angesehen. Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung neuartiger Behandlungen für seltene und verwaiste Krankheiten und zielt darauf ab, unerfüllte Bedürfnisse in unterversorgten Patientengruppen weltweit zu adressieren.
- Significant insider share purchases by CEO and COO, demonstrating confidence in the company's future
- Leadership's commitment to long-term shareholder value
- Company's focus on addressing unmet needs in rare and orphan diseases
- None.
Insights
The insider purchases by Quoin Pharmaceuticals' CEO and COO are a positive signal for investors. While the total investment amount is relatively modest (
However, it's important to note that Quoin's stock price has been volatile and declining over the past year, trading well below
While insider purchases can be encouraging, they don't directly impact Quoin's clinical progress. As a clinical-stage company focusing on rare and orphan diseases, Quoin's value is primarily driven by its pipeline developments and regulatory milestones. Investors should focus on upcoming clinical trial results, potential partnerships and regulatory interactions.
The rare disease market offers significant opportunities due to high unmet needs and potential for premium pricing. However, it also presents challenges in patient recruitment and regulatory hurdles. Quoin's success will depend on its ability to navigate these complexities and demonstrate clear clinical benefits in its target indications.
Purchases Signal Leadership Confidence and Commitment to Company
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company’s American Depositary Shares (ADSs), signaling their confidence in the company’s growth and direction.
On September 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises three products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, without limitation, strong confidence in Quoin’s growth trajectory, delivering long-term value to the Company’s shareholders as the Company advances its mission to address unmet needs in underserved patient populations globally, and Quoin’s three products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, our ability to generate favorable pre-clinical and clinical trial results; costs or delays associated with unsuccessful clinical trials; the Company’s ability to obtain regulatory approvals and the extensive regulatory requirements and future developmental and regulatory challenges the Company will still face even if it obtains approval for a product candidate and other factors identified in the Company’s filings with the SEC. For additional information concerning factors that could cause actual results to differ materially from the information contained in this press release, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 that the Company filed with the SEC and the Company’s subsequent filings with the SEC on Forms 10-Q and 8-K. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
How many ADSs did Quoin Pharmaceuticals' CEO Michael Myers purchase in September 2024?
What was the price range of the ADSs purchased by Quoin Pharmaceuticals' COO Denise Carter?
What is the focus of Quoin Pharmaceuticals (QNRX)?
When did the insider share purchases by Quoin Pharmaceuticals' executives take place?
